183 related articles for article (PubMed ID: 24927340)
1. An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.
Thakral P; Singla S; Yadav MP; Vasisht A; Sharma A; Gupta SK; Bal CS; ; Malhotra A
Indian J Med Res; 2014 Apr; 139(4):544-54. PubMed ID: 24927340
[TBL] [Abstract][Full Text] [Related]
2. In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.
Forrer F; Chen J; Fani M; Powell P; Lohri A; Müller-Brand J; Moldenhauer G; Maecke HR
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1443-52. PubMed ID: 19350237
[TBL] [Abstract][Full Text] [Related]
3. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
Gholipour N; Jalilian AR; Khalaj A; Johari-Daha F; Yavari K; Sabzevari O; Khanchi AR; Akhlaghi M
Daru; 2014 Jul; 22(1):58. PubMed ID: 25074720
[TBL] [Abstract][Full Text] [Related]
4. Impact of DOTA-Chelators on the Antitumor Activity of
Wojdowska W; Karczmarczyk U; Balog L; Sawicka A; Pöstényi Z; Kovács-Haász V; Polyák A; Laszuk E; Mikołajczak R; Garnuszek P
Cancer Biother Radiopharm; 2020 Oct; 35(8):558-562. PubMed ID: 32255676
[No Abstract] [Full Text] [Related]
5. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
[TBL] [Abstract][Full Text] [Related]
6. Standardization of Procedures for the Preparation of (177)Lu- and (90)Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation.
Wojdowska W; Karczmarczyk U; Maurin M; Garnuszek P; Mikołajczak R
Curr Radiopharm; 2015; 8(1):62-8. PubMed ID: 25506704
[TBL] [Abstract][Full Text] [Related]
7. Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.
Cooper MS; Ma MT; Sunassee K; Shaw KP; Williams JD; Paul RL; Donnelly PS; Blower PJ
Bioconjug Chem; 2012 May; 23(5):1029-39. PubMed ID: 22471317
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
[TBL] [Abstract][Full Text] [Related]
9. Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab.
Kameswaran M; Pandey U; Dash A; Samuel G; Venkatesh M
Indian J Med Res; 2016 Jan; 143(1):57-65. PubMed ID: 26997015
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
Yadav MP; Singla S; Thakral P; Ballal S; Bal C
Nucl Med Commun; 2016 Jul; 37(7):735-42. PubMed ID: 26974315
[TBL] [Abstract][Full Text] [Related]
11. Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab.
Forrer F; Oechslin-Oberholzer C; Campana B; Maecke H; Mueller-Brand J; Lohri A
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):544-50. PubMed ID: 23358408
[TBL] [Abstract][Full Text] [Related]
12. Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate
Maaland AF; Heyerdahl H; O'Shea A; Eiriksdottir B; Pascal V; Andersen JT; Kolstad A; Dahle J
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2311-2321. PubMed ID: 31309259
[TBL] [Abstract][Full Text] [Related]
13. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
14. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
Bhusari P; Vatsa R; Singh G; Parmar M; Bal A; Dhawan DK; Mittal BR; Shukla J
Int J Cancer; 2017 Feb; 140(4):938-947. PubMed ID: 27813061
[TBL] [Abstract][Full Text] [Related]
15. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Preclinical Evaluation of (177)Lu-CHX-A"-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma.
Kameswaran M; Pandey U; Dhakan C; Pathak K; Gota V; Vimalnath KV; Dash A; Samuel G
Cancer Biother Radiopharm; 2015 Aug; 30(6):240-6. PubMed ID: 26066665
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).
Kang HJ; Lee SS; Kim KM; Choi TH; Cheon GJ; Kim WS; Suh C; Yang SH; Lim SM
Asia Pac J Clin Oncol; 2011 Jun; 7(2):136-45. PubMed ID: 21585693
[TBL] [Abstract][Full Text] [Related]
18. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
Witzig TE
Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033
[TBL] [Abstract][Full Text] [Related]
19. Optimization of 90 Y-antiCD20 preparation for radioimmunotherapy.
Gholipour N; Vakili A; Radfar E; Jalilian AR; Bahrami-Samani A; Shirvani-Arani S; Ghannadi-Maragheh M
J Cancer Res Ther; 2013; 9(2):199-204. PubMed ID: 23771358
[TBL] [Abstract][Full Text] [Related]
20. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
Grünberg J; Lindenblatt D; Dorrer H; Cohrs S; Zhernosekov K; Köster U; Türler A; Fischer E; Schibli R
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1907-15. PubMed ID: 24859811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
